Mount Sinai Researchers: Why COVID-19 May Be Less Common in Children Than Adults
Findings Published in JAMA Could Lead to Potential Biomarker of Susceptibility
The virus that causes COVID-19 uses a receptor known as ACE2, found on the surface of certain cells in the human body, to enter its victims. Now, Mount Sinai researchers have found that children have lower levels of ACE2 gene expression than adults, which may explain children’s lower risk of COVID-19 infection and mortality. Gene expression is a measure of how much a gene is transcribed. These results, published in JAMA on Wednesday, May 20, may point to a potential biomarker of susceptibility to the virus, known as SARS-CoV-2.
“ACE2 expression may be linked to our susceptibility to COVID-19,” says lead author Supinda Bunyavanich, MD, MPH, Professor of Genetics and Genomic Sciences and Pediatrics, Icahn School of Medicine at Mount Sinai. “ACE2, which stands for angiotensin converting enzyme 2, is a receptor that some might be familiar with because of its role in blood pressure regulation. The coronavirus uses ACE2 to enter the human body, where it spreads. ACE2 is known to be present in our airway, kidneys, heart, and gut. In our study, we took this knowledge a step further, finding that there are low levels of ACE2 expression in the nasal passages of younger children, and this ACE2 level increases with age into adulthood. This might explain why children have been largely spared in the pandemic.”
The research focused on ACE2 due to its significance in COVID-19 infection. The nasal passages are usually the first point of contact for SARS-CoV-2 and the human body. Dr. Bunyavanich’s study is one of only a few examining the relationship between ACE2 in the airway and age.
The retrospective analysis, led by Dr. Bunyavanich, examined nasal passages epithelium from Mount Sinai Health System patients aged 4 to 60. The researchers found ACE2 gene expression in nasal epithelium was age-dependent, lowest in younger children and increasing with age into adulthood.
About the Mount Sinai Health System
Mount Sinai Health System is one of the nation’s leading integrated academic health systems and one of the largest in the New York metropolitan area. The Health System includes approximately 48,000 employees, more than 9,000 physicians, and 8,600 nurses across seven hospitals, more than 400 outpatient practices, over 600 research and clinical laboratories, a school of nursing, and schools of medicine and graduate school of biomedical sciences.
As a leading learning health system, Mount Sinai combines clinical expertise with scientific discovery to improve patient care while training the next generation of health care and biomedical leaders. The Health System provides care across every stage of life, from prenatal care through geriatrics, while advancing personalized medicine through artificial intelligence, data science, and biomedical research.
Mount Sinai is consistently recognized among the nation’s leading academic health systems for patient care, research, and education. The Mount Sinai Hospital is ranked No. 1 in New York and recognized as one of the world’s top Smart Hospital by Newsweek. The Icahn School of Medicine at Mount Sinai ranks No. 11 among U.S. medical schools for National Institutes of Health (NIH) funding and No. 1 among freestanding medical schools, reflecting the strength of its scientific enterprise and leadership in biomedical research.
For more information, visit https://www.mountsinai.org or find Mount Sinai on Facebook, Instagram, LinkedIn, X, and YouTube. To listen to news and stories from Mount Sinai, visit the Mount Sinai Podcast Network.